This phase II trial studies how well ¹⁸F- fluoromisonidazole (FMISO) works with positron
emission tomography (PET)/magnetic resonance imaging (MRI) in assessing participants with
malignant (cancerous) brain tumors. FMISO provides information about the oxygen levels in a
tumor, which may affect how the tumor behaves. PET/MRI imaging produces images of the brain
and how the body functions. FMISO PET/MRI may help investigators see how much oxygen is
getting in the brain tumors.
Phase:
Phase 2
Details
Lead Sponsor:
OHSU Knight Cancer Institute
Collaborators:
National Cancer Institute (NCI) Oregon Health and Science University